Stacy W. Gray, M.D., A.M.

Stacy W. Gray, M.D., A.M., is professor and chief of the Division of Clinical Cancer Genomics within the Department of Medical Oncology & Therapeutics Research and a secondary appointment in the Department of Population Sciences.

Dr. Gray earned her undergraduate degree from Brown University. She received both her master’s degree in public policy and her medical doctorate from University of Chicago. She completed her internal medicine residency and hematology/oncology fellowship at University of Chicago Hospitals.

During her clinical training, she was awarded an Irving B. Harris Fellowship. Subsequently, she completed a research fellowship at the National Cancer Institute-funded Center of Excellence in Cancer Communication Research at University of Pennsylvania’s Annenberg School for Communication.

She continued her research training through a second postdoctoral fellowship at Massachusetts General Hospital, simultaneously joining Dana-Farber as a medical oncologist and cancer outcomes researcher in the Division of Population Sciences and the Lowe Center for Thoracic Oncology.

Dr. Gray's research is in translational genomics. She is working to understand the factors that drive the use of novel and established cancer genomic tests and therapies, identify gaps in lung cancer prevention, research and care, and design interventions to improve the delivery of precision cancer medicine.

Dr. Gray served on the ASCO Cancer Research Committee, holds multiple leadership roles in an National Institutes of Health research consortium, and has presented her research both nationally and internationally. She has numerous peer-reviewed publications in such journals as Journal of Clinical Oncology, Journal of the National Cancer Institute, Journal of Oncology Practice, and Genetics in Medicine.

Dr. Gray also has a strong track record of research funding and has been supported by National Human Genome Research Institute, Agency for Healthcare Research and Quality, American Cancer Society, American Society of Clinical Oncology and Robert Wood Johnson Foundation.

• Demeshko A, Pennisi DJ, Narayan S, Gray SW, Brown MA, McInerney-Leo AM. Factors influencing cancer genetic somatic mutation test ordering by cancer physician, Journal of Translational Medicine, 2020, Nov 12; 18: 431
• Fiero MH, Pe M, Weinstock C, King-Kallimanis BL, Komo S, Klepin HD, Gray SW, Bottomley A, Kluetz PG, Sridhara R. Demystifying the estimand framework: a case study using patient-reported outcomes in oncology, Lancet Oncology, 2020 Oct;21(10)
• de Moor J, Gray SW, Mitchell S, Klaubunde CN, Freedman A. Oncologist confidence in genomic testing and implications for using somatic panel tests in practice, JCO Precis Oncol. 2020 Jun 11;4
• Haggstrom DA, Kahn KL, Klabunde CN, Gray SW, Keating NL. Oncologists’ perceptions of the usefulness of cancer survivorship care plan components, Support Care Cancer. 2020 Jun 14
• Solomon IB, McGraw S, Shen J, Albayrak A, Alverovitz G, Davies M, Del Vecchio Fitz C, Freedman RA, Lopez LN, Sholl L, Van Allen E, Mortimer J, Fakih M, Pal S, Reckamp, Yuan, Gray SW. Engaging patients in precision oncology: Development and usability of a web-based patient-facing genomic sequencing report, JCO Precis Oncol. 2020 Apr 14;4
• Douglas DP, Gray SW, Phillips KA. Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies issued between 2015 -2019, JNCCN. Jul; 18(7): 866-872.
• Keating NL, O'Malley AJ, Onnela JP, Gray SW, Landon BE. Association of physician peer influence with subsequent physician adoption and use of bevacizumab, JAMA Netw Open. 2020 Jan 3; 3(1)
• Robinson JO, Wynn J, Biesecker B, Biesecker LG, Bernhardt B, Brothers KB, Chung WK, Christensen KD, Green RC, McGuire AL, Hart MR, Griesemer I, Patrick DL, Rini C, Veenstra D, Cronin AM, Gray SW. Psychological outcomes related to exome and genome sequencing result disclosure: a meta-analysis of seven Clinical Sequencing Exploratory Research (CSER) Consortium studies. Genet Med. 2019 Dec;21(12):2781-2790
• Keating NL, O'Malley AJ, Onnela JP, Gray SW, Landon BE. Influence of peer physicians on intensity of end-of-life care for cancer decedents, Med Care. 2019 Jun; 57 (6): 468-474
• Slavin TP, Manjarrez S, Prichard CC, Gray S, Weitzel JN. The effects of genomic germline variant reclassification on clinical cancer care. Oncotarget. 2019, Vol 10 (4): 417-423
• Freedman AN, Klaubunde CN, Wiant K, Enewold L, Gray SW, Filipski KK, Keating NL, Leonard DGB, Lively T, McNeel TS, Minasian L, Potosky AL, Rivera DR, Schilsky RL, Schrag D, Simonds NI, Sineshaw HM, Struewing JP, Willis G, deMoor JS. Use of next-generation sequencing tests to guide cancer treatment: Results from a nationally representative survey of oncologists in the United States, JCO Precision Oncology, in press
• Mehta AJ, Stock S, Gray SW, Nerenz DR, Ayanian JZ, Keating NL. Factors contributing to disparities in mortality among patients with non-small cell lung cancer. Cancer Med. 2018 Nov 7 (11):5832-5842
• Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kruzrock R, Weitzel JN. Identification of incidental germline mutations in 10,888 patients with advanced solid tumors who underwent cell-free circulating tumor DNA sequencing, J Clin Oncol. 2018 Oct 19;36(35)
• Slavin TP, Van Tongeren LR, Behrendt CE, Solomon I, Rybak C, Nehoray B, Kuzmich L, Niell-Swiller M, Blazer KR, Tao S, Yang K, Culver J, Sand S, Castillo D, Herzog J, Weitzel JN, Gray SW. Prospective study of cancer genetic variants: Variation in rates of reclassification by ancestry, J Natl Cancer Inst. 2018 Apr 1
• Frosch ZAK, Cronin AM, Gagne JJ, Teschke MP, Gray SW, Abel GA. Cancer drug shortages: Awareness and perspectives from a representative sample of the U.S. Population, Cancer, 2018 May 15;124(10):2205-2211, April 8 [Epub ahead of print]
• Klabunde CN, Haggstron D, Kahn KL, Gray SW, Kim B, Liu B, Eisenstein J, Keating NL. Oncologists’ perspectives on post-cancer treatment communication and care coordination with primary care physicians, European Journal of Cancer Care, Eur J Cancer Care (Engl). 2017 Jul;26(4)
• Gray SW, Gagan J, Cerami E, Cronin AM, Uno H, Oliver N, Lowenstein C, Leederman R, Revette A, Suarez A, Lee C, Bryan J, Sholl L, Van Allen EM. Interactive or static reports to guide clinical interpretation of cancer genomics, J Am Med Inform Assoc. 2018, 2018 May 1;25(5):458-464, Jan 5 [Epub ahead of print]
• Frosch ZAK, Gagne JJ, Gray SW, Abel GA. What does a cancer diagnosis mean? Public expectations in a shifting therapeutic environment, J Oncol Pract. 2018 Mar; 14(3):139-140. Jan 30 [Epub ahead of print]
• Gollust SE, Gray SW, Carere DA, Koenig BA, Lehmann LS, McGuire AL, Sharp RR, Spector-Bagdady K, Wang NA, Green RC, Roberts JS. PGen Study Group, Consumer perspectives on access to direct-to-consumer genetic testing: Roles of demographic factors and the testing experience, Milbank Q. 2017, Jun:95(2):291-318
• Ghazani AA, Oliver NM, St Pierre JP, Garofalo A, Rainville IR, Hiller E, Treacy DJ, Rojas-Rudilla V, Wood S, Bair E, Parello M, Huang F, Giannakis M, Wilson FH, Stover EH, Corsello SM, Nguyen T, Rana HQ, Church AJ, Lowenstein C, Cibulskis C, Amin-Mansour A, Heng J, Brais L, Santos A, Bauer P, Waldron A, Lo P, Gorman M, Lydon CA, Welch M, McNamara P, Gabriel S, Sholl LM, Lindeman NI, Garber JE, Joffe S, Van Allen EM, Gray SW, Janne PA, Garraway LA, Wagle N. Assigning clinical meaning to somatic and germline whole-exome sequencing data in a prospective cancer precision medicine study, Genet Med. 2017 Jul;19(7):787-79. Epub 2017 Jan 26